Analysts' Opinions on Sarepta

News

FDA to Ask Sarepta to Halt Elevidys Shipments

Sarepta tells FDA it won’t halt shipments despite patient deaths

In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy.

U.S. News & World Report · 15h

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy

Bloomberg on MSN · 1d

Sarepta Refused FDA’s Request to Halt Elevidys Shipments

Sarepta Therapeutics Inc. has refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies, the Food and Drug Administration said Friday.

Fierce Biotech1d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

BioSpace2d

Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

TipRanks on MSN19h

JPMorgan, Starbucks, HPE, Sarepta, Elevance: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($JPM) ), ( ($SBUX) ), ( ($HPE) ), ( ($SRPT) ) and ( ($ELV) ). Here is a breakdown of their recent ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY)

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Asianet Newsable on MSN1d

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage ...

1don MSN

Sarepta Therapeutics Stock Tumbles on Report of Third Death in Clinical Trial

Shares of Sarepta Therapeutics plummeted Friday following a report that a third patient has died during a clinical trial for ...

Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Nasdaq1y

12 Analysts Have This To Say About Sarepta Therapeutics

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

Business Insider1y

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...

Sarepta: Finally, A Little Relief For Bulls; I Expect More

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Nasdaq11mon

26 Analysts Have This To Say About Sarepta Therapeutics

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ: SRPT), expressing a variety of opinions spanning from bullish to bearish. The table below ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results